A higher percentage of patients treated with an experimental Pfizer Inc drug for osteoporosis died during a clinical trial compared with a placebo, U.S. drug reviewers said in an analysis released on Thursday.
The higher proportion of deaths through five years was statistically significant only for the lowest dose of the drug called Fablyn, said Food and Drug Administration reviewers. More patients given Fablyn, which was co-developed with Ligand Pharmaceuticals Inc, also developed blood clots.
More...
FDA staff note deaths in Pfizer bone drug study
An influenza outbreak has reportedly sickened more than 150 recruits in training at Lackland air force...
On Wednesday, the New York Knicks overcame a 29-point deficit to defeat the San Antonio Spurs...
A provision in last year’s One Big Beautiful Bill Act blocked Planned Parenthood’s health centers from...
